Reported Earlier, HUTCHMED Publishes Phase III Sovleplenib Results, 48.4% Response Rate In ITP Patients Versus 0% In Placebo Group

— Publication shows treatment demonstrated durable response rate of 48.4% vs. 0% with placebo —
 

— Presentations at EHA showcased subgroup analyses demonstrating consistent benefits regardless of prior lines of therapies or prior TPO/TPO-RA1 exposure —

— Data supported regulatory submission in China accepted in January 2024 —